- Home
- CSPI vs CHRS Comparison
CSPI vs CHRS Comparison
Compare CSPI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSPI
- CHRS
- Stock Information
- Founded
- CSPI 1968
- CHRS 2010
- Country
- CSPI United States
- CHRS United States
- Employees
- CSPI N/A
- CHRS N/A
- Industry
- CSPI EDP Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSPI Technology
- CHRS Health Care
- Exchange
- CSPI Nasdaq
- CHRS Nasdaq
- Market Cap
- CSPI 174.4M
- CHRS 191.3M
- IPO Year
- CSPI 1987
- CHRS 2014
- Fundamental
- Price
- CSPI $16.25
- CHRS $1.39
- Analyst Decision
- CSPI
- CHRS Strong Buy
- Analyst Count
- CSPI 0
- CHRS 4
- Target Price
- CSPI N/A
- CHRS $5.38
- AVG Volume (30 Days)
- CSPI 38.1K
- CHRS 2.0M
- Earning Date
- CSPI 02-12-2025
- CHRS 03-12-2025
- Dividend Yield
- CSPI 0.71%
- CHRS N/A
- EPS Growth
- CSPI N/A
- CHRS N/A
- EPS
- CSPI N/A
- CHRS N/A
- Revenue
- CSPI $55,219,000.00
- CHRS $304,340,000.00
- Revenue This Year
- CSPI N/A
- CHRS $2.47
- Revenue Next Year
- CSPI N/A
- CHRS N/A
- P/E Ratio
- CSPI N/A
- CHRS N/A
- Revenue Growth
- CSPI N/A
- CHRS 44.19
- 52 Week Low
- CSPI $10.06
- CHRS $0.66
- 52 Week High
- CSPI $29.93
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- CSPI 50.20
- CHRS 45.86
- Support Level
- CSPI $15.15
- CHRS $1.38
- Resistance Level
- CSPI $16.44
- CHRS $1.60
- Average True Range (ATR)
- CSPI 1.09
- CHRS 0.13
- MACD
- CSPI -0.16
- CHRS -0.03
- Stochastic Oscillator
- CSPI 41.69
- CHRS 9.52
About CSPI CSP Inc.
CSP Inc along with its subsidiaries develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments namely Technology Solutions, where the company focus on value-added reseller integrated solutions including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company design, manufacture and deliver products and services to customers that require specialized cyber security services, networking and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates its maximum revenue from the Americas.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.